pcn poster

Posters

The Effect of Dual Orexin Receptor Antagonists on Next-Day Driving: A Systematic Review and Meta-Analysis

This meta-analysis of dual orexin receptor antagonists illustrates that the impact of treatment on next-day driving performance varies across treatments within the DORA drug class.

Margaret Moline , PhD;

10/26/2023

The Effectiveness of using escitalopram in Pediatric GAD and the Methods to Predict the treatment response: a Systematic Review and Meta-analysis

this is the first Systematic review that discussed the use of the escitalopram in GAD in pediatric patients, regarding use, safety efficacy, and possible treatment prediction methods and ...

10/26/2023

The effects of Covid-19 on Health Insurance and Mental Health

Our hypothesis postulates that those who had employer-based insurance were negatively affected and those who had public insurance were positively affected. Those who were on public insura...

Andrew Kim , PhD, MPH;

10/26/2023

The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial

IDgenetix is the only clinically validated pharmacogenomic test that combines drug-drug interactions (DDI) and lifestyle factors with drug-gene interactions and demonstrates improved outc...

Feng Cao , PhD;

10/26/2023

The Rapid Mood Screener (RMS) for Bipolar I Disorder: Study Design for a Confirmatory Study Evaluating Performance in Real-World Settings

This large, cross-sectional, observational study will be conducted in a sample reflecting bipolar I disorder prevalence in real-world settings to confirm the performance of the Rapid Mood...

Huy-Binh Nguyen ;

10/26/2023

Sustained Improvements in Chorea Associated With Huntington Disease With Once-Daily Valbenazine: Interim Results From a Long-Term Open-Label Study

KINECT™-HD2 is an ongoing, long-term open-label study of once-daily valbenazine for chorea associated with Huntington disease. Pre-planned interim analyses indicate early chorea improveme...

Joyce Y. Cheng , MD, MHS, MSN, PMHNP-BC;

10/26/2023

Sleep Disturbances Are Highly Predictive of Major Depressive Disorder Recurrence

This longitudinal study evaluated the impact of sleep disturbances, including hypersomnolence, on the progress of major depressive disorder (MDD) over a 3-year period. Participant charact...

Venkatesh Ganapathy , MD;

10/26/2023

SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of TV-44749 for Subcutaneous Use (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia

Intramuscular long-acting injectable olanzapine is approved for treatment of schizophrenia in adults but has an associated risk for post-injection delirium/sedation syndrome. The Subcutan...

Kelli R. Franzenburg , PhD;

10/26/2023

Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm

This post-hoc analysis of two phase 3 studies demonstrates that solriamfetol, an approved treatment for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea, ...

Sean Hammond , PhD;

10/26/2023

Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-controlled Study of Sleep Apnea Participants (SHARP)

Solriamfetol is a dopamine-norepinephrine reuptake inhibitor (DNRI) that improves wakefulness in adults with EDS and OSA. Beyond inhibiting DAT/NET, solriamfetol demonstrated agonist acti...

Gregory Parks ;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products